Results 1 to 10 of about 5,082,017 (204)

Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy

ACS Nano, 2022
Most patients are at high risk of thrombosis during cancer treatment. However, the major discrepancy in the therapeutic mechanisms and microenvironment between tumors and thrombosis makes it challenging for a panacea to treat cancer while being able to eliminate the risk of thrombosis.
Kai Zhang, Zhaoyu Ma, Shuting Li, Weiyun Zhang, Mohamed Frahat Foda, Yanli Zhao, Heyou Han   +6 more
semanticscholar   +7 more sources

Biomimetic nanoparticles co-deliver hirudin and lumbrukinase to ameliorate thrombus and inflammation for atherosclerosis therapy

Asian Journal of Pharmaceutical Sciences
Atherosclerosis (AS) is a progressive inflammatory disease, and thrombosis most likely leads to cardiovascular morbidity and mortality globally. Thrombolytic drugs alone cannot completely prevent thrombotic events, and treatments targeting thrombosis ...
Mengying Cheng, Tianxiang Yue, Hong Wang, Lai Jiang, Qiaoling Huang, Fanzhu Li   +5 more
doaj   +4 more sources

In situ formed depot of elastin-like polypeptide-hirudin fusion protein for long-acting antithrombotic therapy. [PDF]

Proc Natl Acad Sci U S A
Thrombosis, induced by abnormal coagulation or fibrinolytic systems, is the most common pathology associated with many life-threatening cardio-cerebrovascular diseases. However, first-line anticoagulant drugs suffer from rapid drug elimination and risk of hemorrhagic complications. Here, we developed an in situ formed depot of elastin-like polypeptide (
Tian X, Feng M, Wei X, Cheng C, He K, Jiang T, He B, Gu Z.   +7 more
europepmc   +4 more sources

Self-regulated hirudin delivery for anticoagulant therapy [PDF]

Science Advances, 2020
Polymeric nanogel with on-demand release of hirudin prevents and inhibits clot formation.
Xiao Xu, Xuechao Huang, Ying Zhang, Shiyang Shen, Zhizi Feng, He Dong, Can Zhang, Ran Mo   +7 more
openaire   +3 more sources

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease

Asian Journal of Pharmaceutical Sciences, 2022
Cardiovascular disease is the leading cause of global mortality, with anticoagulant therapy being the main prevention and treatment strategy. Recombinant hirudin (r-hirudin) is a direct thrombin inhibitor that can potentially prevent thrombosis via ...
Mengfang Wu, Tian Xia, Yaran Li, Tianfa Wang, Shijia Yang, Jinchao Yu, Qiaoyan Liang, Teng Shen, Min Yu, Bing Zhao   +9 more
doaj   +2 more sources

R-Hirudin as Anticoagulant in Regular Hemodialysis Therapy: Finding of Therapeutic R-Hirudin Blood/Plasma Concentrations and Respective Dosages [PDF]

Clinical and Applied Thrombosis/Hemostasis, 1999
Recently heparin-induced thrombocytopenia type II has been diagnosed more frequently and does not exclude hemodialysis patients. Up to now, recombinant hirudin is the only available anticoagulant showing no immunologic cross reactions with heparin. However, the use of r-hirudin in hemo dialysis patients with different degrees of residual renal func ...
E, Bucha, G, Nowak, R, Czerwinski, H, Thieler   +3 more
openaire   +3 more sources

A Biomimetic Macrophage-Membrane-Fused Liposomal System Loaded with GVs-HV Recombinant Plasmid for Targeted Anti-Atherosclerosis Therapy. [PDF]

Pharmaceutics
Background: Cardiovascular disease is one of the leading causes of death worldwide. The presence of atherosclerotic plaques in the arteries leads to continuous growth and obstruction of blood vessels, which ultimately leads to acute myocardial infarction
Zhang Y, Gu W, Yu K, Chen Q, Wang H, Wei Y, Zheng H, Zheng H, Liu L, Li F.   +9 more
europepmc   +2 more sources

Traditional Chinese medicine in the treatment of diabetic kidney disease: the mechanisms of signaling pathways regulations [PDF]

Frontiers in Endocrinology
Diabetic kidney disease (DKD) represents a diabetes-driven microvascular complication characterized by renal physiological and metabolic disorders and is considered a top-ranking trigger of progression to end-stage renal disease and death in diabetic ...
Wencan Li, Chaoqi Lei, Qinxuan Wu, Keqian Chen, Zheng Liu, Qichang Xing, Xiang Liu, Jiani Zhang   +7 more
doaj   +2 more sources

Anti-atherosclerotic effects between a combined treatment with simvastatin plus hirudin and single simvastatin therapy in patients with early type 2 diabetes mellitus

Annals of Translational Medicine, 2019
This study aimed to investigate the efficacy and safety of simvastatin plus hirudin in preventing atherosclerosis in the patients with early type 2 diabetes mellitus (T2DM).This was a 24-week, randomized, open-label and controlled study in which 150 outpatients initially diagnosed with T2DM were randomly assigned into either simvastatin (40 mg daily at
De-Qiang, Li, Fei-Fei, Lv, Zhong-Chun, Li, Zhi-Yuan, Dai, Hong-Xia, Wang, Yang, Han   +5 more
openaire   +3 more sources

Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation [PDF]

Circulation, 2001
Background —The development of thrombocytopenia in acute coronary syndromes (ACS) appears to be associated with adverse clinical outcomes. Unfractionated heparin is a recognized cause of thrombocytopenia, but the incidence, predictors, and prognostic significance of thrombocytopenia during hirudin therapy in ACS have not been ...
J W, Eikelboom, S S, Anand, S R, Mehta, J I, Weitz, C, Yi, S, Yusuf   +5 more
openaire   +3 more sources